-Picard Medical / SynCardia Systems LLC mark historic milestone as a patient reaches 2,900 days of continuous support with the SynCardia Total Artificial Heart -- the longest timeframe in the world ever recorded- TUCSON, Ariz., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, proudly marks a new milestone in the fi ...

Core Insights - OpenAI is preparing to launch four new models, collectively referred to as the "Penguin family," with varying inference budgets, indicating a strategic enhancement in their AI capabilities [1][10] - The new models include Emperor (512), Rockhopper (64), Macaroni (16), and Mumble (0), with Emperor being the flagship model [3][10] - A new "memory search" feature is being developed for ChatGPT, aimed at improving user experience by allowing quick retrieval of stored memory information during conversations [5][21] Model Developments - The Emperor model has the highest inference budget of 512, positioning it as a state-of-the-art flagship model [3][10] - The Rockhopper model, with an inference budget of 64, serves as a mid-tier option, while Macaroni is designed for quick and efficient inference with a budget of 16 [10] - Mumble, with no inference budget, is designed for rapid responses, showcasing a diverse range of capabilities within the Penguin family [10] Memory Search Feature - The "memory search" function aims to streamline the user experience by allowing users to retrieve relevant memory entries through direct prompts, addressing current usability issues [21][22] - This feature is expected to enhance workflow efficiency and context retrieval, similar to functionalities found in other applications like the Atlas browser [22][24] - The introduction of this feature is seen as a strategic move to retain existing users and attract new ones amid increasing competition in the AI assistant market [24][26] Competitive Landscape - OpenAI's market share has been impacted by competitors like Google's Gemini 3, which has led to a 6% decline in daily active users for ChatGPT [24] - There are speculations that OpenAI may expedite the release of GPT-5.2 in response to competitive pressures, potentially launching it sooner than expected [29] - The company is also facing backlash from users regarding the introduction of ads in ChatGPT, which has led to subscription cancellations [26][28]

Core Insights - Picard Medical, Inc. has strengthened its intellectual property portfolio with the grant of U.S. Patent No. 12,383,722 B2 for its next-generation SynCardia Total Artificial Heart (STAH), named "Emperor" [1][2] - The company now holds a total of 34 patented claims in the U.S. related to its next-generation total artificial heart system, with additional protection in China [1][2] - The Emperor is designed to be fully implantable and provide pulsatile flow without the need for an external pneumatic driver [1] Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is based in Tucson, Arizona, and is the leader in commercially available total artificial heart technology for patients with end-stage heart failure [4] - The SynCardia Total Artificial Heart is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the U.S. and Canada [4] - Over 2,100 implants have been performed at hospitals across 27 countries, making the SynCardia Total Artificial Heart the most widely used and extensively studied artificial heart globally [4] Strategic Goals - The company aims to expand its patent portfolio globally to protect its innovative technologies, including durable mechanisms, advanced electronics, and wireless implantable features [2][3] - The patent portfolio is seen as a foundation for the company's future, securing the path from development to commercialization and ensuring long-term global leadership in heart replacement technology [3]